

TCAR

TransCarotid Artery Revascularization


A NEW TREATMENT OPTION FOR CAROTID ARTERY DISEASE

Treating Carotid Disease


Carotid artery disease is estimated to be the source of stroke in up to a third cases and there are 400,000 new diagnoses of carotid artery disease made every year in the United States.

Most cases of carotid artery disease, similar to other vascular diseases caused by atherosclerosis, are medically managed. Carotid intervention is indicated when:

- Symptomatic patients with stenosis $\geq 50\%$
- Asymptomatic patients with stenosis $\geq 80\%$



Coronary Artery Disease





“The overall **stroke rate** of **1.4%** is the **lowest reported to date** for any prospective, multi-center trial of carotid stenting”

J Vasc Surg 2015; 62:1227-35

TCAR is a patient-friendly, endovascular procedure that incorporates the neuroprotection principles of CEA. It utilizes the ENROUTE® Transcarotid Neuroprotection System to temporarily reverse blood flow away from the brain, collecting any potential debris in the device filter, before returning the blood to a vessel in the leg. With reverse flow neuroprotection established, the ENROUTE® Transcarotid Stent is then implanted in the lesion for long-term plaque stabilization and stroke prevention.

TCAR is well-suited for patients who are at higher risk of surgical complications, due to age, medical comorbidities, or anatomical issues. The TCAR Surveillance Project, a quality initiative led by the Society of Vascular Surgeons, has established Medicare coverage and reimbursement for symptomatic and asymptomatic patients.



Actual debris captured in filters

For more information:



ANDREW BOWSER, MD, FACS
BOARD CERTIFIED, GENERAL AND VASCULAR SURGERY
(830) 990-1404

Offices in Boerne, Fredericksburg and Kerrville

HillCountryMemorial.org